ODN 2216
Based on 1 publication(s) in Google Scholar
ODN 2216 is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 interacts with TLR9 in the lysosomes of CD4+ T cells and activates feedback-dependent signaling pathways. ODN 2216 induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 not only induces the differentiation of CD4+ T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8+ T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 is widely used in studies related to breast cancer and systemic lupus erythematosus.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.57%
- CAS No.: 332437-00-0
- Masse moléculaire:6432.00
-
Stockage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) ODN 2216
More
Activité biologique
|
TLR9 |
IL-12 |
ODN 2216 (10 μM; 16 h pre-treatment, 9 days co-culture, 48 h cytotoxicity assay) does not significantly enhance MamA2.1-specific activation of primary HLA-A2+ CD8+ T cells or subsequent MamA-specific cytotoxicity against AU565 breast cancer cells compared to MamA2.1 peptide alone[1].
ODN 2216 (3 μM; 24 h) induces TLR9-mediated IFN-α secretion by human PBMCs after 24 hours of incubation at a concentration of 3 μM[2].
ODN 2216 (0.5-10 μM; 4 days) dose-dependently increases intracellular ATP and IL-6 levels in human PBMCs[2].
ODN 2216 (500 ng/mL; 14 hours) physically interacts with intracellular TLR9 in lysosomes of human CD4+ CD25- T cells following 14-hour incubation with 500 ng/mL ODN 2216 FITC[3].
ODN 2216 (500 ng/mL; 72 hours) induced increased proliferation of human CD4+ CD25- T cells, which is dependent on TLR9 signaling via TLR9, MyD88, IRAK1, and TRAF3, but not IRF7[3].
ODN 2216 (500 ng/mL; 48 hours) treated human CD4+ CD25- T cells acquire dose-dependent suppressive activity against untreated autologous CD4+ T cells, with maximum suppression (48.57%) at a 4:1 suppressor:responder ratio[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Thymic DC, pDC
-
Concentration:2 μM
-
Incubation Time:15 h
-
Result:Significantly decreased apoptosis of thymic DC (23.1 ± 0.9%), and naturally induced apoptosis of thymic pDC was not decreased (72.8 ± 2.9%).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
DNA, d(G-sp-G-sp-G-G-G-A-C-G-A-T-C-G-T-C-G-sp-G-sp-G-sp-G-sp-G-sp-G)
Chemical Information
-
CAS No. 332437-00-0
-
Appearance Solid
-
Masse moléculaire 6432.00
-
Color White to off-white
-
SMILES
[DNA, d(G-sp-G-sp-G-G-G-A-C-G-A-T-C-G-T-C-G-sp-G-sp-G-sp-G-sp-G-sp-G)]
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Immunity
Polyamine metabolism controls B-to-Z DNA transition to orchestrate DNA sensor cGAS activity. [Abstract]2023 Nov 14;56(11):2508-2522.e6. PMID: 37848037
Pureté et documentation
-
Fiche technique (271 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2242 KB)
Références
[1]. Krug A, et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol. 2001 Jul;31(7):2154-63. [Content Brief]
[2]. Okada T, et al. Murine thymic plasmacytoid dendritic cells. Eur J Immunol. 2003 Apr;33(4):1012-9. [Content Brief]
[3]. Huang L, et al. CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner. Oncogene. 2017 Jul 13;36(28):4081-4086. [Content Brief]
[4]. He Y, et al. Hepatic mitochondrial DNA/Toll-like receptor 9/MicroRNA-223 forms a negative feedback loop to limit neutrophil overactivation and acetaminophen hepatotoxicity in mice. Hepatology. 2017 Jul;66(1):220-234. [Content Brief]
[5]. Li Y, et al. A novel antagonist of TLR9 blocking all classes of immunostimulatory CpG-ODNs. Vaccine. 2011 Mar 3;29(11):2193-8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz